Exelixis Inc., of South San Francisco, reported net revenues of $4.3 million for the fourth quarter and $31.3 million for the full year, including net product revenues of $4.3 million and $15 million, respectively, for the fourth quarter and full year sales of Cometriq (cabozantinib), which was launched in January 2013 for medullary thyroid cancer.